FDA clears Tucatinib regimen for HER2-positive breast cancer maintenance
The FDA approved Pfizer's Tucatinib, used with trastuzumab and pertuzumab, as maintenance treatment after induction therapy for adults with unresectable locally advanced or metastatic HER2-positive breast cancer. The decision is supported by the phase 3 HER2CLIMB-05 study, in which median progression-free survival was 24.9 months with the regimen and 16.3 months with placebo. The updated label includes a boxed warning for severe liver toxicity.
Why it matters
The clearance moves Pfizer's drug into first-line maintenance care, expanding its approved use to patients whose disease has not progressed after induction treatment. Pfizer said the regimen provides a chemotherapy-free maintenance option.
Key facts
- 1The FDA authorized tucatinib with trastuzumab and pertuzumab for maintenance therapy after induction treatment in eligible adults with HER2-positive breast cancer. ajmc.com
- 2HER2CLIMB-05 enrolled 654 patients and compared tucatinib 300 mg twice daily with placebo, with both groups receiving trastuzumab and pertuzumab. ajmc.com
- 3Median progression-free survival was 24.9 months for tucatinib and 16.3 months for placebo. medscape.com
- 4Adding tucatinib cut the risk of progression or death by 35.9% in the trial. ajmc.com
- 5The tucatinib label carries a boxed warning for severe hepatotoxicity. medscape.com
- 6Overall-survival results were immature at the time of analysis. medscape.com
Open questions
- Reported grade 3 or higher adverse-event rates differ across the materials: 42% versus 42.3% for tucatinib and 24% versus 24.4% for placebo.
- Reported treatment-discontinuation rates due to adverse events differ across the materials: 13% versus 13.8% for tucatinib.
- Reported diarrhea rates differ across the materials: 73% versus 72.7%, with grade 3 or higher diarrhea at 6% versus 6.1%.
Summary written by AlphAI from 3 of 3 sources. Not investment advice. Figures are as stated by the linked sources.